Skip to main content
    B

    Bioatla Inc (BCAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.56
    -0.13 (-7.69%)

    Market Cap: $2.89M

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Bioatla Inc (BCAB) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    Bioatla reported revenue of $2.00M for the fiscal year ended Dec 31, 2025, down 81.8% from the year before. That year, net income was -$59.61M with a net margin of -2980.3%, operating cash flow was -$48.20M and free cash flow was -$48.20M. The quarter ended Sep 30, 2026 had revenue of $250.00K and net income of -$7.90M.

    Revenue and Margins

    Over the 7 years to Dec 2025, revenue fell from $10.63M, a compound annual decline of 21.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.00M-81.8%100.0%-2965.3%-2980.3%
    Dec 2024$11.00MN/A100.0%-672.2%-634.3%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$250.00K-41.7%100.0%-38576.0%-38160.8%
    Dec 2020$429.00K-91.8%100.0%-7016.1%-8357.3%
    Dec 2019$5.20M-51.1%100.0%-543.6%-574.1%
    Dec 2018$10.63MN/A-147.5%-265.7%-272.7%
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$2.00M$11.00M$0$0$250.00K$429.00K$5.20M$10.63M
    Cost of revenue$0$0$0$0$0$0$0$26.30M
    Gross profit$2.00M$11.00M$0$0$250.00K$429.00K$5.20M-$15.68M
    Research and development$43.57M$63.09M$103.73M$79.35M$58.27M$19.93M$25.92M$26.30M
    Operating income-$59.30M-$73.94M-$129.69M-$108.14M-$96.44M-$30.10M-$28.27M-$28.23M
    Net income-$59.61M-$69.78M-$123.46M-$106.48M-$95.40M-$35.85M-$29.86M-$28.98M
    EBITDAN/A-$72.22M-$128.55M-$106.93M-$95.11MN/AN/A-$27.24M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$250.00K$6.50M$0$2.00M$0$0$0$0$11.00M$0$0$1.71M
    Gross profit$250.00K$6.50M$0$2.00M$0$0$0-$11.65M$11.00M$0$0-$368.00K
    Operating income-$8.36M$227.00K-$9.31M-$9.26M-$13.79M-$18.65M-$17.61M-$16.24M-$11.27M-$21.97M-$24.46M-$28.54M
    Net income-$7.90M$452.00K-$6.34M-$9.78M-$15.78M-$18.71M-$15.33M-$14.88M-$10.59M-$21.07M-$23.23M-$26.93M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.43M by $5.69M. Shareholder equity was negative, at -$36.19M, as total liabilities of $50.02M exceeded total assets of $13.83M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$13.83M$52.42M$119.66M$225.74M$254.42M$244.94M$9.34M$16.64M
    Current assets$8.01M$51.23M$116.41M$220.43M$247.29M$240.68M$4.51M$12.66M
    Cash and equivalents$7.12M$49.05M$111.47M$215.51M$244.98M$238.60M$3.70M$10.86M
    Total liabilities$50.02M$38.16M$48.99M$45.40M$43.60M$34.96M$65.35M$45.08M
    Short-term debt$1.43M$836.00K$1.62M$1.52M$1.39M$682.00K$9.71MN/A
    Long-term debtN/AN/AN/A$0N/A$682.00K$8.41M$15.00M
    Shareholder equity-$36.19M$14.27M$70.67M$180.34M$210.82M$209.97M-$55.96M-$28.46M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.11M$9.51M$8.57M$13.83M$15.91M$27.13M$38.29M$52.42M$62.24M$68.64M$89.20M$119.66M
    Total liabilities$44.70M$45.74M$45.88M$50.02M$47.15M$43.87M$37.74M$38.16M$39.27M$37.27M$39.48M$48.99M
    Cash and equivalents$576.00K$1.54M$1.96M$7.12M$8.32M$18.21M$32.36M$49.05M$56.52M$61.66M$80.63M$111.47M
    Shareholder equity-$43.60M-$36.24M-$37.31M-$36.19M-$31.24M-$16.75M$547.00K$14.27M$22.97M$31.37M$49.72M$70.67M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$48.20M-$71.94M-$104.02M-$90.42M-$62.21M-$36.33M-$9.64M-$35.32M
    Capital expenditures$0$0$98.00K$268.00K$924.00K$590.00K$1.51M$988.00K
    Free cash flow-$48.20M-$71.94M-$104.11M-$90.69M-$63.14M-$36.92M-$11.15M-$36.30M
    Dividends paidN/AN/AN/AN/A$0$19.00K$5.00KN/A
    Investing cash flow$0$0-$98.00K-$265.00K-$924.00K-$590.00K-$1.51M-$988.00K
    Financing cash flow$6.28M$9.51M$77.00K$61.21M$69.51M$271.82M$4.00M$5.02M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$967.00K-$419.00K-$5.27M-$7.92M-$9.88M-$14.12M-$16.29M-$16.78M-$5.13M-$19.19M-$30.83M-$29.92M
    Capital expendituresN/AN/A$0$0$0$14.20M$0$0$0$0$0$8.00K
    Free cash flowN/AN/A-$5.27M-$7.92M-$9.88M-$28.32M-$16.29M-$16.78M-$5.13M-$19.19M-$30.83M-$29.93M
    Last 12 quarters

    Frequently Asked Questions About BCAB

    What is Bioatla's annual revenue?

    Bioatla reported revenue of $2.00M for the fiscal year ended Dec 31, 2025.

    How fast is Bioatla's revenue growing?

    Revenue was down 81.8% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Bioatla profitable?

    No. Bioatla reported net income of -$59.61M for the fiscal year ended Dec 31, 2025, with a net margin of -2980.3%.

    How much free cash flow does BCAB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$48.20M minus capital expenditures of $0 produced free cash flow of -$48.20M.

    How much debt does Bioatla have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.43M and cash and equivalents of $7.12M.